bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

## 1 Enhanced FcyRIII/CD16 activation by discrete ligands as independent correlates of

## 2 disease severity in COVID-19 patients

- 3
- 4 Jakob Ankerhold<sup>1,2,11</sup> & Sebastian Giese<sup>1,2,11</sup> & Philipp Kolb<sup>1,2,11</sup>, Andrea Maul-Pavicic<sup>3,4</sup>,
- 5 Nathalie Göppert<sup>1,2</sup>, Kevin Ciminski<sup>1,2</sup>, Clemens Kreutz<sup>5</sup>, Achim Lother<sup>6,7</sup>, Ulrich Salzer<sup>3</sup>,
- 6 Wolfgang Bildl<sup>8</sup>, Tim Welsink<sup>9</sup>, Nils G. Morgenthaler<sup>9</sup>, Andrea Busse Grawitz<sup>10</sup>, Daniela
- 7 Huzly<sup>1,2</sup>, Martin Schwemmle<sup>1,2</sup>, Hartmut Hengel<sup>1,2,12</sup>, Valeria Falcone<sup>1,2,12</sup>
- 8
- <sup>1</sup>Institute of Virology, University Medical Center, Albert-Ludwigs-University Freiburg,
   Hermann-Herder-Str. 11, 79104 Freiburg, Germany
- <sup>11</sup> <sup>2</sup>Faculty of Medicine, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany
- 12 <sup>3</sup>Department of Rheumatology and Clinical Immunology, Medical Center-University of
- 13 Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55, 79106 Freiburg,
- 14 Germany
- <sup>4</sup>Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Faculty
- 16 of Medicine, University of Freiburg, Breisacherstr. 115, 79106 Freiburg, Germany
- <sup>5</sup>Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center,
- 18 University of Freiburg, Stefan Meier Str. 26, 79104 Freiburg, Germany
- 19 <sup>6</sup>Heart Center Freiburg University, Department of Cardiology and Angiology I, Faculty of
- 20 Medicine, University of Freiburg, Hugstetterstr. 55, 79106 Freiburg, Germany
- 21 <sup>7</sup>Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine,
- 22 University of Freiburg, Albertstr. 25, 79104 Freiburg, Germany
- <sup>8</sup>Institute of Physiology II, Faculty of Medicine, University of Freiburg, Hermann-Herder-Str.
- 24 Freiburg, Germany
- 25 <sup>9</sup>InVivo BioTech Services GmbH, 16761 Hennigsdorf, Germany
- 26 <sup>10</sup>Institute of Clinical Chemistry and Laboratory Medicine, Medical Center University of
- 27 Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55, 79106 Freiburg,
- 28 Germany
- 29 <sup>11</sup>contributed equally
- 30 <sup>12</sup>corresponding authors
- 31
- 32
- 33

## 34 One sentence summary

- 35 Severity of disease in COVID-19 patients is associated with enhanced CD16 activation by
- 36 afucosylated S-specific IgG and CD16-reactive circulating IgG-complexes.
- 37

#### 38 Abstract

39 A dysregulated immune response with high levels of SARS-CoV-2 specific IgG antibodies is a common and distinctive feature of severe or critical COVID-19. Although a robust IgG 40 41 response is typically considered to be beneficial, an overshooting activation mediated by 42 immune receptors recognizing the Fc part of IgG (FcyRs) is thought to be detrimental and 43 immunopathology. However, direct evidence of FcyR driven associated with 44 immunopathology in COVID-19 is still sparse. Here, we used a cell-based FcyR activation reporter system to systematically analyze SARS-CoV-2 specific IgG responses and IgG-45 46 mediated FcyRIII (CD16) activation profiles in COVID-19 patient cohorts categorized by 47 severity of disease. We found that increased CD16 activation by SARS-CoV-2 specific IgG is 48 associated with a known pro-inflammatory IgG modification, namely afucosylation. Further, 49 we identified CD16-reactive soluble IgG immune complexes (sICs) to be present in the serum of COVID-19 patients and show that the resulting CD16 activation by sICs is strongly related 50 51 to disease severity. Our results provide evidence that CD16 activation by pro-inflammatory 52 SARS-CoV-2 specific IgG together with circulating sICs is a major contributor to COVID-19 53 immunopathology. These findings highlight the importance of FcyR driven immunopathology 54 in COVID-19. Further, our data highly warrant the development of targeted intervention 55 strategies against IgG driven immunopathology following SARS-CoV-2 infection.

### 58 Introduction

Since the emergence of SARS-CoV-2 in late December 2019<sup>1</sup>, more than 178 million 59 laboratory confirmed infections (as of June 21, 2021) have been reported, with cases 60 61 continuously rising<sup>2</sup>. Accordingly, rapid insights into the disease manifestations and pathogenesis have been globally obtained. A hallmark of the coronavirus disease 2019 62 63 (COVID-19) is a respiratory infection which can progress to an acute respiratory distress 64 syndrome (ARDS). Next to asymptomatic infections, COVID-19 symptoms differ widely 65 according to the disease process and may comprise fever, coughing, pneumonia, dyspnea, hypoxia and lymphopenia<sup>3</sup>. While fever and coughing are common symptoms, pneumonia, 66 67 hypoxia, dyspnea, certain organ manifestations and lymphopenia indicate critical or fatal infections. Pronounced dyspnea can eventually progress to ARDS, a severe complication 68 frequently observed in critically ill patients<sup>4</sup>. Although disease severity and in particular 69 breathing difficulties are related to viral load<sup>5</sup>, age<sup>6-8</sup> and underlying medical conditions<sup>7,8</sup>, the 70 kinetics of respiratory failure strongly suggest an essential role of the host immune 71 response<sup>3,7</sup>. Typically, aggravation occurs between 9-12 days after symptom onset<sup>8</sup> and 72 73 correlates with high levels of SARS-CoV-2 specific IgG antibodies and systemic effects of pro-inflammatory cytokines such as IL-6 and  $TNF\alpha^{3,9,10}$ . This cytokine release, primarily the 74 result of macrophage and T helper (T<sub>H</sub>) cell activation<sup>11</sup>, includes pattern recognition receptor 75 76 (PRR) signaling in the context of innate immunity but also Fcy receptor (FcyR) activation<sup>12</sup>. 77 Triggered by immune complexes (antibody-antigen complex), the cytokine release following 78 FcyR activation represents a potent defense mechanism against invading pathogens. A 79 prototypical activating FcyR in this regard is FcyRIII (CD16) expressed by NK cells and monocyte-derived macrophages (CD16A)<sup>13</sup> or neutrophils (CD16B, 98% sequence identical 80 ectodomains). Specifically, CD16 is able to recognize circulating soluble immune complexes 81 (sICs) as they are formed in certain autoimmune diseases such as lupus<sup>14-17</sup> and viral 82 infections<sup>18</sup>. Overstimulation of activating FcyRs in these cases is associated with disease 83 severity<sup>18-20</sup> and thus an FcyR-driven overshooting inflammatory response<sup>12</sup> might be an 84 85 explanation for the pronounced immunopathology observed during severe courses of COVID-19<sup>21</sup>. Consistently, hyper-inflammation in SARS-CoV-1 and MERS infected patients has been 86 previously proposed as a possible pathogenic factor<sup>22</sup> and could be demonstrated in mice and 87 SARS-CoV-1<sup>23,24</sup>. Furthermore, N297-dependent glycan-88 infected with macaques modifications such as afucosylation within the constant region of SARS-CoV-2 specific IgG 89 90 antibodies enhance binding to FcyRs, in turn driving inflammation. Enhanced FcyR activation

by low-fucosylated anti-SARS-CoV-2-S IgG leading to excessive alveolar macrophage
 activation has specifically been shown to drive severe COVID-19 disease progression<sup>25</sup>.

93 Therefore we aimed to delineate the contribution of IgG-mediated effector functions 94 regarding COVID-19 severity in patient cohorts with various severity of SARS-CoV-2 95 infection. We monitored antigen-specific IgG responses in patients with mild, critical and 96 severe COVID-19 disease with regard to titer, kinetics and CD16 activation. This revealed a 97 marked correlation between CD16 activation by patient IgG and severity of disease. 98 Additionally, we identified circulating sICs to be abundantly present in the serum of critically 99 and severely diseased patients, but not in the serum of those with a mild disease. As sICmediated CD16 activation independently correlates with disease severity, we provide 100 101 evidence that also sIC formation is indicative of disease progression. Our findings enable new 102 avenues of intervention against COVID-19 and highly warrant further investigation into the 103 origin and composition of sICs in COVID-19.

- 104
- 105

### 106 **Results**

### 107 **Patients and clinical information.**

We retrospectively analyzed serial serum samples collected for routine diagnostic testing from 108 109 41 patients hospitalized at our tertiary care center between March and June 2020 with SARS-110 CoV-2 infection confirmed by real-time PCR. Based on the clinical course, we categorized 111 patients as either severely diseased (hospitalized with COVID-19 related pneumonia) versus 112 critically diseased (COVID-19 related pneumonia and eventually in need of invasive 113 mechanical ventilation). In total, 27 patients with critical and 14 with severe courses of 114 disease were grouped into separate cohorts (Table 1). Most patients were older than 60 years 115 with an overall mean age of 68 years (63 years and 76 years in the critically and severely 116 diseased patients respectively).

117 The majority of patients in both groups had comorbidities of different origin with 118 cardiovascular diseases including hypertension representing the most frequent pathology 119 (35/41, 85%). Similar to previous reports, high Interleukin 6 (IL-6) and C-reactive protein 120 (CRP) levels were associated with severity of disease (Ø IL-6: 1452.1 pg/ml in the critical 121 group vs 46.1 pg/ml in the severe group and Ø CRP: 162.2 mg/l vs 65.3 mg/l Ø13-25 days 122 post symptom onset respectively). Similarly, procalcitonin, a biomarker of microbial 123 coinfection, was significantly higher in critically diseased patients (Ø value 9.9 ng/ml vs 0.17 124 ng/ml). Bacterial superinfection represented a further complication in 39% of the patients and

125 was only slightly more frequent in patients with critical disease (11/27, 41% vs 5/14, 33%).

126 More than half of the patients (59%) were treated with hydroxycloroquine/Kaletra®, (18/27,

127 67% in the critical group vs 6/14, 43% in the severe group). Notably, at the time of serum

- 128 acquisition, only one patient received steroid treatment, which was given due to underlying
- 129 chronic obstructive pulmonary disease. Finally, mortality rate was 37% (10/27) in critically
- 130 and 7% (1/14) in severely diseased patients.
- 131

## 132 Kinetics of IgG antibody responses following symptom onset across severe and critical133 courses of disease.

It has been proposed that elevated SARS-CoV-2 antibody titers are associated with disease 134 severity<sup>10</sup> and may play a role not only in the clearance but also in the pathogenesis of SARS-135 136 CoV-2 infection<sup>26</sup>. We therefore initially analyzed the levels and kinetics of SARS-CoV-2 137 specific IgG in serial serum samples from patients hospitalized with critical (n=27) or severe 138 (n=14) illness, a setting we also used in the following experiments. A total of 125 (critically 139 diseased) and 79 (severely diseased) serum samples, obtained from the aforementioned 140 patients at different time points within 6-25 days following symptom onset were analyzed by 141 commercially available S1- and N- specific ELISA-based assays. Assay specificity was 142 confirmed analyzing healthy donor (HD) serum samples (n=30) as negative control (Figure 1-143 figure supplement 1 A, B). Most patients developed detectable SARS-CoV-2 specific IgG responses within 9-14 days after symptom onset. SARS-CoV-2 specific IgG gradually 144 145 increased over time in both severely and critically diseased patients reaching a plateau at 18-146 20 days after symptom onset (Figure 1 A, B). Varying antibody response kinetics were 147 observed for each individual patient (Figure 1-figure supplement 2 A-D) with anti-N IgG 148 titers rising significantly earlier than anti-S1 IgG (12.5 days  $\pm$  3.3 days vs 10.6  $\pm$  3.8; p= 149 0.0091). A trend towards earlier seroconversion for anti-S1 IgG could be observed in 150 critically diseased patients (mean time of seroconversion  $11.4 \pm 3.0$  days in critically diseased 151 patients vs  $12.9 \pm 3.8$  days for severely diseased patients; p = 0.24), whereas time of 152 seroconversion for anti-N IgG was similar in both groups ( $10.1 \pm 3.2$  and  $10.4 \pm 4.2$  days for critically and severely diseased patients, respectively; p = 0.83). S1- and N-specific IgG levels 153 154 at plateau did not significantly differ between the two groups. No significant difference 155 between deceased and discharged patients was measured 13-25 days after symptom onset 156 (Figure 1- figure supplement 1 C, D, E). Next, we evaluated and compared the neutralizing 157 capacity of SARS-CoV-2 IgG in either critically versus severely diseased patients in a plaque-158 reduction assay (Figure 1 C). All patients mounted a robust neutralizing antibody response

159  $(91\% \pm 10.5\%$  neutralization at a 1:64 serum dilution), with peaking titers at 18-20 days 160 following symptom onset. Of note, two critically diseased patients developed a neutralizing 161 response already at 6-8 days after symptom onset. In summary, we observed only minor 162 differences in cohort wide kinetics of S1- or N- specific IgG levels between patients 163 hospitalized with severe or critical clinical courses indicating that antibody levels per se did 164 not correlate with severity of disease in our study.

165

## Patients with severe COVID 19 show enhanced CD16 activation by S-specific IgG antibodies.

FcyRIII (CD16) activation initiates multiple protective effector functions such as antibody-168 dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells as well as antibody-169 dependent cytokine and chemokine secretion by NK cells and macrophages<sup>12,27</sup>. However, 170 171 excessive FcyR stimulation can have severe adverse effects such as elevated cytokine release as observed in autoimmune diseases or viral infections<sup>12</sup>. Therefore, we hypothesized that an 172 173 exaggerated FcyR mediated activation triggered by SARS-CoV-2 specific IgG might 174 contribute to the exacerbation of COVID-19 in severely compared to critically diseased 175 patients. To address this, we analyzed the ability of SARS-CoV-2 specific antibodies to activate CD16 (158V) using a previously established cell-based reporter system<sup>28</sup> (Figure 2-176 177 figure supplement 1A). Considering the typically late time point of health deterioration, we 178 performed an analysis of CD16 activation triggered by SARS-CoV-2 specific IgG on serum 179 samples obtained 13-25 days following symptom onset (Figure 2). Sera were analyzed at a 180 1:500 dilution to stay within the dynamic range of detection (Figure 2- figure supplement 2). 181 Depending on the availability of sample material 2-8 samples/patient/time-point were 182 included in this analysis. If available in sufficient quantity, sera were reanalyzed. 183 Reproducibility was tested using available serum surplus (Figure 2- figure supplement 3). 184 Sera from 28 patients with mild SARS-CoV-2 infection and 30 healthy blood donors were 185 included for reference. Semi-quantitative assessment of IgG titers using antigen-specific 186 ELISA revealed comparable levels between critically and severely diseased patient cohorts 187 (Figure 2 A, B, C). In contrast, S- (p=0.0147) and RBD-specific (p=0.0120) but not N-188 specific IgG-mediated CD16 activation was significantly increased in critically compared to 189 severely diseased patients (Figure 2 D-F). Furthermore, normalizing CD16 activation to 190 antigen-specific IgG titers, revealed significantly stronger CD16 activation by S- (p=0.0033) 191 and N-specific (p=0.006) IgG compared to mildly diseased patients (Figure 2 G-I). 192 Intriguingly, we observed a heterogeneous CD16 activation pattern characterized by either

high or low CD16-activating sera irrespective of the clinical manifestation (Figure 2 D-F).
Overall, a significant positive correlation could be determined between anti-SARS-CoV-2
antigen IgG titers and CD16 activation (Figure 2-figure supplement 4). Our data document a
sustained CD16 activation by SARS-CoV-2 specific antibodies particularly in patients
suffering from critical COVID-19 disease. Based on these results we confirmed the notion
that elevated FcγRIII activation by S- and or RBD-specific IgG might contribute to disease
severity of COVID-19.

200

## 201 Enhanced Fcγ-afucosylation of S-specific IgG in critically and severely diseased patients 202 results in increased CD16 activation.

We speculated that differences in Fcy mediated effector functions might contribute to disease 203 204 severity of COVID-19 and thus compared CD16 high- versus CD16 low-activating patient 205 sera regarding their SARS-CoV-2 specific IgG core fucosylation. Inspired by previous findings<sup>29-31</sup> we focused on determining IgG core fucosylation of S- and N- specific SARS-206 207 CoV2 IgG. To determine IgG core fucosylation we adapted a lectin-based ELISA preceded by 208 antigen-specific antibody purification from immobilized SARS-CoV-2-antigen. Analysis of 209 anti-S and anti-N IgG core fucosylation was performed on serum pools containing five sera of 210 either critically or severely diseased patients obtained 13-25 days post symptom onset. Given 211 the aforementioned heterogeneity in CD16-activation, we analyzed pools of 5 sera of either 212 critically or severely diseased patients characterized by either high or low CD16-activation. To 213 stay within the dynamic detection range, relative fucosylation was analyzed at a dilution of 214 1:4 (Figure 3). When analyzing serum pools from critically and severely diseased patients we 215 determined a significantly lower level of core fucosylation among the high CD16 activators 216 (Figure 3, plain-colored bars) compared to the low CD16 activators (Figure 3, shaded bars). 217 This applied for both the S- and N-specific antibodies. These results are in line with 218 previously published findings regarding the effect of Fcy-afucosylation on CD16 effector functions<sup>29,32</sup> and recapitulate similar findings in the context of COVID-19<sup>30,31</sup>. However, we 219 220 did not observe significant differences between critically and severely diseased patients.

221

# 222 COVID-19 disease severity correlates with an increase in CD16-reactive soluble IgG 223 complexes.

Aside from afucosylation, it has been proposed that uncleared antigen-antibody immune complexes (ICs) might further exacerbate inflammation, explaining complications observed in COVID-19 such as cytokine storm, systemic vasculitis, microvascular thrombosis and organ

failure<sup>33-35</sup>. However, the presence of circulating, soluble ICs (sICs) in critically or severely 227 228 diseased patients has not been conclusively shown yet. As extensive FcyR activation by sICs 229 might contribute to the severe systemic inflammatory state occurring in some COVID-19 230 patients with prolonged disease, we surmised that sICs might be a putative explanation for the 231 marked differences in IL-6, PCT and CRP levels between critically and severely diseased 232 patients (Table 1). We thus set out to characterize our patient cohort regarding the presence of 233 sICs in serum samples taken at various time points during disease and after hospitalization. To 234 this end, we deployed a novel cell-based reporter assay developed to quantify CD16 (158V) activation by IgG-containing sICs<sup>17</sup>. As recently shown, the assay does not react to 235 236 monomeric IgG or small dimeric complexes in solution, but specifically identifies multimeric 237 sICs and has been successfully used to identify sICs in patients with systemic lupus erythematosus (SLE)<sup>16</sup>. Moreover, the assay is sensitive to sICs size with larger complexes 238 239 leading to stronger receptor activation compared to small complexes. Analysis of serum 240 samples, obtained 13-25 days after symptom onset, revealed the presence of highly CD16-241 reactive sICs in SARS-CoV-2 infected patients compared to healthy individuals (Figure 4A). 242 Next, we compared sIC-mediated CD16 activation between COVID-19 patients of varying 243 disease severity. While all COVID-19 patient groups tested positive for reactive sICs compared to healthy control (HD) sera, we found that critically diseased patients show a 244 245 striking increase in reactive sICs compared to patients with severe or mild disease (Figure 246 4B). Only 6 out of 27 patients with critical disease (22%) showed no sIC-mediated CD16 247 activation. As we did not detect reactive sICs in the serum of 47 patients with acute 248 respiratory distress syndrome (ARDS; mean age 57.5 years) in response to infections of 249 different etiology including CMV reactivation, HIV, influenza or TBC infection, we conclude 250 that the formation of reactive sICs is associated with severe SARS-CoV-2 disease (Figure 4-251 figure supplement 1). Longitudinal analysis of reactive sICs in the serum of critically or 252 severely diseased patients revealed high CD16 activation levels in 4 critically diseased patients already 6 to 8 days after symptom onset (Figure 4C). Of note, 2 of 4 patients with an 253 254 early increase of circulating reactive sIC eventually died. sIC-mediated CD16 activation 255 persisted in 14 of 19 critically diseased patients at high levels until day 26 after symptom 256 onset. sIC-mediated CD16 activation in severely diseased patients was slightly delayed 257 compared to critically diseased patients and was first detected in 4 patients 9-11 days after symptom onset (Figure 4C). Only 4 of 14 patients with severe disease showed detectable sIC-258 259 mediated CD16 activation. To verify that sICs represent the CD16-reactive component in the 260 serum of COVID-19 patients, we analyzed serum-mediated CD16 activation before and after

261 PEG8000-precipitation. This treatment was previously shown to selectively precipitate large 262 IgG complexes from solution<sup>36</sup>. For this analysis, pools of 8 sera, showing either high (IC+) 263 or no (IC-) CD16 activation, were compared. Sera from healthy donors (HD) served as a 264 negative control. Compatible with the hypothesis of serum-derived sICs driving CD16 265 activation, no activation was observed following incubation with 3.5% PEG8000 (Figure 4-266 figure supplement 2 A). To ensure, that the treatment did not precipitate monomeric IgG, we 267 tested the depleted sera for remaining S1- and N-specific IgG. As depicted S1- and N-268 specific IgG could still be detected at high levels in samples treated with 3.5% PEG8000 269 (Figure 4-figure supplement 2 B). When resolving sIC-mediated CD16 activation over the 270 complete time of hospitalization for select patients from which samples at different time 271 points were available, we observed that sIC reactivity follows a similar course as anti-S1 IgG 272 titers in ELISA (Fig. 4-figure supplement 3). While this might imply that sIC formation 273 involves SARS CoV-2 S1 antigen, we were not able to identify any SARS-COV-2-derived 274 antigens in PEG8000-precipitated sICs using tandem mass spectrometry (data not shown). To 275 further exclude the formation of multimeric sICs formed from circulating S1 antigen, we also 276 specifically targeted S1 for precipitation from patient serum using biotinylated S1-specific 277 monoclonal antibodies. However and in line with our previous approach, S1-specific 278 precipitation using streptavidin-sepharose beads and subsequent mass spectrometry analysis 279 for any SARS-CoV-2-specific antigens in sICs remained inconclusive (data not shown). 280 Recently, the role of neutrophil mediated intravascular NETosis was found to play a critical 281 role in thrombose formation and subsequent organ damage observed in severe clinical forms 282 of COVID-19<sup>37</sup>. Since this process could mediate the formation of aggregated IgG as a form 283 of sICs, we next tested whether Benzonase® nuclease treatment of patient serum would 284 dissolve reactive sICs. To this end we tested sera from critically diseased patients or healthy 285 individuals and compared CD16 reactivity before and after nuclease treatment (Figure 4-286 figure supplement 4). Nuclease activity in diluted human serum was controlled using plasmid 287 DNA for reference. This revealed that nucleic acid was not involved in the formation of 288 CD16-reactive sICs in critically diseased patients. Finally, we tested pooled patient sera for 289 autoantibodies against a panel of prototypical autoantigens associated with autoimmune disease including anti-nuclear autoantibodies (ANA) by indirect immunofluorescence, 290 291 dsDNA autoantibodies by ELISA and autoantibodies against the extractable nuclear antigens 292 (nRNP/Sm, Sm, SS-A, Ro-52, SS-B, Scl-70, PM-Scl, Jo-1, CENP B, PCNA, nucleosomes, 293 histones, ribosomal P-protein, AMA-M2, DFS70) by dot blot in case SARS-CoV-2 infection 294 triggers autoantibody formation and possible sIC formation. However, no significant

autoantibody titers could be detected in any sera pool (data not shown). Although we were not able to identify their origin, our data clearly indicates the presence of circulating sICs in COVID-19 patients with an increase in CD16-reactive sICs corresponding with severity of disease. Accordingly, we conclude that circulating sICs are a hitherto unknown, yet contributing factor to COVID-19 disease severity and, regarding infectious diseases, our findings represent an observation unique to severely diseased COVID-19 patients.

301

#### 302 **Discussion**

We collected and analyzed data from 41 COVID-19 patients hospitalized at the University Hospital Freiburg. Patients were categorized by severity of disease into severely (n=14) and critically diseased patients (n=27). Both groups were of comparable average age and had a similar male-to-female ratio. For comparison we also analyzed 28 mildly diseased and 30 healthy individuals. As key findings we identify the potential of *de novo* produced SARS-CoV-2 IgG and the presence of soluble immune complexes activating FcγRIII/CD16 as independent risk factors closely associated with severe courses of COVID-19.

310

#### 311 CD16 activation by SARS-CoV-2 specific IgG is increased in critically diseased patients.

FcyR activation by anti-viral IgG represents a potent defense mechanism, directing the 312 313 immune response to the site of viral replication<sup>38-41</sup>. However, persistent infection can lead to prolonged stimulation of FcyRs, driving an overshooting and potentially damaging 314 315 inflammatory response<sup>12,18</sup>. A potential key component in prolonged inflammation following 316 SARS-CoV-2 infection is FcyR mediated cytokine and chemokine release by several immune 317 cells as their activation has been implied in severity of disease<sup>29,31,42</sup>. Along these lines, 318 glycan profiles of anti-SARS-CoV2 IgG have been identified as major correlates of COVID-319 19 disease progression<sup>29-31</sup>. As these modifications particularly affect CD16 activation, we 320 characterized our patient groups with regard to CD16 activation by S- and N-specific IgG and 321 determined significantly increased CD16 activation by S, N and RBD specific IgG in sera 322 from severely and critically diseased patients compared to mildly diseased patients. We 323 further identified a higher level of afucosylation being indicative of COVID-19 severity, which is in line with previous studies<sup>29-31</sup>, and now directly link this general observation to an 324 325 increased CD16 activation. Taken together, we find that CD16 activation by SARS-CoV-2-326 specific IgG can be directly correlated to IgG glycan modifications and disease severity.

#### 328 Circulating sICs contribute to COVID-19 disease severity

329 Based on the herein presented results identifying CD16 activation to be a major correlate of 330 disease severity, we further explored this using an adapted FcyR activation assay optimized to 331 measure soluble immune complexes  $(sICs)^{17}$ . Indeed, we provide first evidence of such 332 circulating sICs in the serum of COVID-19 patients and experimentally confirm previous 333 hypotheses suggesting immune complexes as potential drivers of disease progression in 334 COVID-19<sup>33-35</sup>. In fundamental contrast to opsonized antigens decorating virus-infected cells, 335 sICs become distributed systemically. Thus constitutive activation of CD16<sup>+</sup> monocytes, 336 granulocytes and NK cells could readily explain systemic responses which potentiate local 337 inflammation in virus-infected tissues intensifying organ damage and dysfunction. Although the origin of the circulating immune complexes still remains elusive, we clearly show that the 338 339 presence of IgG-containing sICs is restricted to SARS-CoV-2 infection and that complexed 340 IgG is directly responsible and sufficient for the observed CD16 activation by patient serum. 341 As we find sIC reactivity to roughly follow SARS-CoV2-S specific IgG responses, we 342 speculated that circulating S or shed S1-antigens might still be involved in sIC formation, 343 albeit in a form we were not able to detect. In support of this hypothesis, it has recently been 344 published that circulating S-antigen can be detected in the plasma of individuals who received two doses of the mRNA-1273 (Moderna) vaccine<sup>43</sup>. S1 shedding was also reported to play a 345 346 role in virion infectivity as the introduction of a D614G mutation significantly enhanced infectivity due to an increased S-protein density in the virion<sup>44</sup>. Finally, others have identified 347 348 potential mechanisms leading to S-antigen shedding in viral infection and proposed a link 349 between the presence of circulating S-antigen and disease severity<sup>45</sup>. Alternatively, IgG autoantibodies of diverse specificity might cause the formation of the CD16 triggering sICs we 350 351 herein identified. In fact, several studies have described that auto-antibodies can be frequently 352 detected in critically ill COVID-19 patients<sup>46-48</sup>. In particular, very recent work shows that an 353 acute SARS-CoV-2 infection triggers the de novo IgG production against multiple 354 autoantigens. Interestingly, 60-80% of all hospitalized COVID-19 patients had anti-cytokine IgG (ACA)<sup>49</sup>. The authors show that ACA levels and specificity change over time during 355 356 hospitalization, suggesting ACA induction in response to viral infection and inflammation. 357 Further, it has been shown that pre-existing neutralizing anti-type I interferon antibodies, 358 which can be found in about 10% of patients with severe COVID-19 pneumonia, are related to the highest risk of developing life-threatening COVID-19 disease<sup>50</sup>. Therefore, the *de novo* 359 360 induction of anti-cytokine auto-antibodies in a large proportion of hospitalized COVID-19 patients as described by Chang et al<sup>49</sup>, might indeed represent the origin of circulating sICs in 361

362 COVID-19. In such a scenario, immune responses are deviated first by depletion of important 363 cytokines and second through the formation of pathological sICs which trigger immunological 364 damage. We show that critically diseased patients show significantly higher levels of reactive 365 sICs compared to less severely diseased patients. In addition, sIC responses can be found 366 significantly earlier in critically diseased patients, which was associated with a fatal disease 367 outcome. We also find that patients show a wide range of sIC reactivity. According to the Heidelberger-Kendall precipitation curve<sup>51</sup>, sIC size is critically dependent on the 368 369 antigen: antibody stoichiometry. As the used FcyR activation assay is sensitive to sIC size<sup>17</sup>, it 370 is highly likely that this also plays a role when measuring COVID-19 patient serum. As some 371 patients show high anti-SARS-CoV-2-S IgG titers in the absence of sICs and vice versa we 372 speculate that sIC size plays a role in CD16 reactivity. Therefore, we propose that in addition 373 to the presence of sICs, the size of sICs plays a role in CD16 driven COVID-19 374 immunopathology.

375 Taken together, we conclude that CD16 activation in COVID-19 disease is governed by IgG 376 glycan profiles and sIC formation (Figure 5) and plays a major role in disease progression and 377 severity. Indeed, there is evidence in this direction from a clinical perspective provided by a 378 recent study that finds the administration of intravenous immunoglobulin (IVIg) to alleviate 379 COVID-19 disease<sup>52</sup>. Although no direct proof, this heavily implies that the saturation of 380 FcyRs mitigates immunopathology. Therefore, our findings provide an explanation for the 381 sustained immunopathology following SARS-CoV-2 infection as well as for the efficacy of 382 IVIg treatment in severe to critical COVID-19 disease.

- 383
- 384

## 385 Material and Methods

386

## 387 Subjects and specimens

388 Between March 2020 and April 2020, 41 patients with SARS-CoV-2 infection confirmed by 389 real-time PCR were hospitalized in the University Medical Center, Freiburg. Serum samples 390 were collected during hospitalization for routine laboratory testing. Clinical data were 391 obtained from electronic medical records. A total of 27 patients necessitating invasive 392 mechanical ventilation were included in the critical group. Fourteen patients requiring O<sub>2</sub> 393 supplementation were included in the severe group. Additionally, serum samples from 29 394 mild COVID-19 cases and 30 healthy donor (HD) plasma samples were used as controls in 395 this study.

396

## 397 Cell culture

398 African green monkey kidney Vero E6 cells (ATCC CRL-1586) were cultured at 37°C in 399 Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (vol/vol) fetal calf 400 serum (FCS, Biochrom), sodium pyruvate (1x, Gibco) and 100 U/ml penicillin-Streptomycin 401 (Gibco). BW5147 mouse thymoma cells (BW, obtained from ATCC: TIB-47) were stably transduced with human Fc $\gamma$ R as previously described<sup>53</sup>. Cells were maintained at  $3x10^5$  to 402 403 9x10<sup>5</sup> cells/ml in Roswell Park Memorial Institute medium (RPMI GlutaMAX, Gibco) 404 supplemented with 10% (vol/vol) FCS, sodium pyruvate (1x, Gibco), 100 U/ml penicillin-405 Streptomycin (Gibco) β-mercaptoethanol (0.1 mM, Gibco). Cells were cultured at 37°C, 5% 406 CO<sub>2</sub>. All cell lines were routinely tested for mycoplasma.

407

## 408 Monitoring of antibody response to SARS-CoV-2 by ELISA

409 Serum IgG antibody titers targeting S1- and N-SARS-CoV-2 proteins were measured using 410 commercial enzyme-linked immunosorbent assay (ELISA). Anti-S1- SARS-CoV-2 IgG was 411 measured by the anti-SARS-CoV-2 ELISA (IgG) Euroimmune Kit (Euroimmune, Lübeck, 412 Germany) according to manufacturer's protocol. Results, expressed as arbitrary units (AU), 413 were evaluated semi-quantitatively by calculation of the ratio of the extinction of the control 414 or patient sample over the extinction of the calibrator. This ratio is interpreted as follows: < 415 0.8 negative;  $\geq$  0.8 to <1.0 borderline;  $\geq$  1.1 positive. Anti-N SARS-CoV-2 IgG was detected 416 using the recomWell SARS-CoV-2 IgG Kit (Mikrogen Diagnostik GmbH, Neuried, 417 Germany) according to manufacturer's protocol. The corresponding antibody activity 418 expressed in AU/ml is calculated using the formula (absorbance of sample / absorbance of 419 cut-off)  $\times$  20. Result are interpreted as follow: < 20 negative;  $\geq$  20 to < 24 borderline; > 24 420 positive. IgG against the SARS-CoV-2 Spike Glycoprotein Receptor Binding Domain (RBD) 421 were detected using SARS-CoV-2 IgG ELISA Reagent Set, kindly provided by InVivo 422 (InVivo Biotech Services GmbH, Hennigsdorf, Germany) according to manufacturer's 423 protocol.

424

## 425 Fcy receptor activation assay

426 FcγRIIIA (CD16A, 158V) activation was measured by a cell-based assay as previously
427 described<sup>28</sup>. For detection of anti-S and anti-RBD-specific FcγR activation we utilized SARS428 CoV-2-S- and RBD-coated plates (kindly provided by InVivo Biotech Services GmbH,
429 Hennigsdorf, Germany). The recombinant (S)-protein was produced under serum-free

430 conditions in mammalian cells and contains amino acid residues 1 to 1213 of the SARS-CoV-431 2 Wuhan-Hu-1-isolate (GenBank annotation QHD43416.1). The furin cleavage site was 432 mutated, two mutations for protein stabilization were included, and the C-terminal domain 433 was replaced by a T4 trimerization sequence and a C-terminal hexa-His-Tag<sup>54</sup> The recombinant RBD-protein represented amino acids 319 to 541 of the (S)-protein mentioned 434 435 before. Both recombinant proteins were purified using immobilized metal exchange 436 chromatography (IMAC) and preparative SEC under standard conditions in a regulated 437 environment. Microtiter plates were coated using 0.2 µg recombinant (S)-protein or RBD-438 protein per well. N-specific FcyR activation was determined using plates coated with SARS-439 CoV-2-N (Mikrogen Diagnostik GmbH, Neuried, Germany). Respective plates were subsequently incubated with serial dilutions of SARS-CoV-2 positive sera or control sera in 440 441 RPMI supplemented with 10% (vol/vol) FCS for 30 min at 37°C. All wells were thoroughly 442 washed before co-cultivation with BW5147 reporter cells for 16 h at 37°C, 5% CO<sub>2</sub>. Cross-443 link activation of reporter cells was performed by direct coating of target antibody to ELISA 444 plate (Nunc Maxisorp; 96 well, flat transparent), followed by a blocking step and incubation 445 with  $2 \times 10^5$  reporter cells per well. For all activation assays, mouse IL-2 secretion was quantified by anti-IL-2 ELISA, as described earlier. FcyRIIIA (CD16A) activation by sICs 446 was measured by a recently developed cell-based assay<sup>17</sup>. Briefly, 2x10<sup>5</sup> BW5147-CD16 447 448 reporter cells were incubated with SARS-CoV-2 sera in a total volume of 200 µl for 16 h at 449 37°C, 5% CO<sub>2</sub>. Incubation was performed in a 96-well ELISA plate (Nunc Maxisorp) pre-450 treated with PBS containing10% FCS for 1 h at 4°C to avoid direct binding of serum IgG to 451 the plate. Reporter cell mIL-2 secretion was quantified via ELISA as described previously<sup>28</sup>.

452

## 453 Purification of SARS-CoV2-S and –N specific antibodies from serum

454 SARS-CoV-2-specific antibodies were purified using SARS-CoV-2 spike protein (S)-coated 455 plates (kindly provided by InVivo BioTech Services) and - nucleocapsid (N) - coated plates 456 recomWell SARS-CoV-2 IgG (Mikrogen Diagnostik GmbH, Neuried, Germany). Patient sera 457 were diluted 1:5 in 100 µl (two wells per serum sample) and incubated for one hour at 37°C 458 with the S- and N-precoated plates. After washing using PBS-T (0.05% Tween 20) 100 mM 459 formic acid (30 µl/well) was added and incubated for 5 min on an orbital shaker at room 460 temperature (RT) to elute bound IgG. Following pH neutralization using TRIS buffer (1 M), 461 the eluates were either directly processed or stored at 4°C.

462

#### 463 Quantitation of antigen-specific IgG amount

In order to determine the relative S1- and N-SARS-CoV-2 specific IgG antibody
concentration of the generated eluates, S1- and N-ELISA were performed by the anti-SARSCoV-2 ELISA (IgG) Euroimmune Kit (Euroimmune, Lübeck, Germany) and anti-N SARSCoV-2 IgG ELISA (recomWell SARS-CoV-2 IgG Kit (Mikrogen Diagnostik GmbH,
Neuried, Germany) as aformentioned.

469

## 470 Analysis of antigen-specific IgG-Fcγ fucosylation

471 Fucosylation levels of S- and N-specific IgG were measured using a lectin-based ELISA 472 assay. Briefly, 96-well Maxisorb plates (Nunc®) were coated with 50µl/well anti-human IgG-473 Fab fragment (MyBiosource, MBS674607) at a concentration of  $2 \mu g/ml$ , diluted in PBS for 474 one hour at 37°C. After three washing steps with PBS-T (0.05% Tween20) unspecific binding sites were blocked adding 300 µl/well Carbo-free<sup>TM</sup> blocking solution (VectorLab, Inc., SP-475 476 5040, LOT: ZF0415) for one hour at room temperature. After three further washing steps, 477 eluted antibodies were 2-fold serially diluted with PBS in a total volume of 30 µl/well and 478 incubated for one hour at 37°C and 5% CO<sub>2</sub>. After washing (3x) using PBS-T, 50 µl/well of 4 479 µg/ml biotinylated Aleuria Aurantia lectin (AAL, lectin, VectorLab, B-1395) diluted in lectin 480 buffer (10 mM HEPES, 0.1 mM CaCl<sub>2</sub>, 0.15 M NaCl, 0.1% Tween20) was added and 481 incubated for 45 min at room temperature (RT). Following another three washing steps using 482 PBS-T, Streptavidin-Peroxidase Polymer (Sigma, S 2438), at 1 µg/ml final concentration 483 diluted in LowCross-HRP®-buffer (Candor, Order #.: 200 500) was added and incubated for 484 one hour at RT. After washing five times with PBS-T, 50 µl/well of 1-Step<sup>™</sup> Ultra TMB-485 ELISA Substrate Solution (ThermoFisher, 34028) was applied and the enzyme-substrate 486 reaction was stopped after six minutes using 50 µl/well sulphuric acid (1 M H<sub>2</sub>SO<sub>4</sub>). 487 Quantification of absorbance, OD<sub>450nm</sub>, was performed using a Tecan M2000.

488

#### 489 **PEG Precipitation**

Sera pools, consisting of eight different sera per pool, were diluted with varying amounts of PEG8000, in order to reach a final PEG8000 concentration of 1, 2, 3.5, 5 and 7.5% respectively. Mixtures were vortexed and incubated overnight at 4°C. For supernatant analysis, precipitates were sedimented via centrifugation at 13.000 rpm for 30 minutes at 4°C. For Mass Spectrometry analysis, PEG8000-precipitated sICs were shortly run into 10% polyacrylamide gels. After over-night fixation (40% ethanol, 10% acetic acid, 50% water) and washing (3x), complete lanes were excised.

#### 498 **Benzonase treatment of sera**

Serum from six individual patients containing CD16-reactive soluble immune complexes, were treated with 250 units (U) of Benzonase Nuclease (Sigma-Aldrich Chemie Gmbh, Munich Germany) for 1 h at 4°C. After treatment, sera were titrated in complete BW5147 culture medium and tested for CD16 reactivity. Non-treated sera served as control. To verify Benzonase activity in the presence of human serum, 3  $\mu$ g of pIRES-eGFP plasmid DNA (Addgene) were digested with 250 U of Benzonase. Successful nucleic acid digestion was visualized using a 1% agarose gel stained with Midori Green.

506

#### 507 Immune precipitation

508 For mass spectrometry analysis of SARS-CoV2-S specific precipitates, individual sera 509 containing CD16-reactive soluble immune complexes were subjected to immune precipitation 510 (IP) using Pierce MS-compatible magnetic IP kit (ThermoFisher Scientific, Darmstadt, 511 Germany) according to manufacturer's protocol. Briefly 250 µl serum was incubated 512 overnight at 4°C with 5 µg of biotinylated anti-RBD-specific TRES-1-224.2.19 mouse 513 monoclonal antibody or TRES-II-480 (isotype control) (kind gift of H.M. Jäck, Erlangen) 514 before addition of streptavidin magnetic beads. Beads were subsequently collected via 515 centrifugation and elution buffer was added to detach putative precipitated antigen. The 516 elution was dried in a speed vacuum concentrator and shortly run into 10% polyacrylamide 517 gels. After over-night fixation (40% ethanol, 10% acetic acid, 50% water) and washing (3x), 518 complete lanes were excised. Antibody biotinylation was performed using a Pierce antibody 519 biotinylation Kit for IP (ThermoFisher Scientific, Darmstadt, Germany) according to 520 manufacturer's protocol.

521

### 522 Mass Spectrometry

523 Proteins were in-gel digested with sequencing grade modified trypsin (Promega GmbH, Walldorf, Germany) similar to the procedure described by Pandey et al.<sup>55</sup>. Vacuum-dried 524 525 peptides were dissolved in 0.5% trifluoroacetic acid, loaded onto a trap column (C18 526 PepMap100, 5 µm particles, Thermo Fisher Scientific GmbH, Dreieich, Germany) with 527 0.05% trifluoroacetic acid (4 min, 10 µL/min) and separated on a C18 reversed phase column 528 (SilicaTip<sup>TM</sup> emitter, 75 µm i.d., 8 µm tip, New Objective, Inc, Littleton, USA, manually 529 packed 23 cm with ReproSil-Pur ODS-3, 3 µm particles, Dr. A. Maisch HPLC GmbH, 530 Ammerbuch-Entringen, Germany; flow rate: 300 nL/min). For sample injection and multistep gradient formation (eluent "A": 0.5% acetic acid in water; eluent "B": 0.5% acetic acid in 531

532 80% acetonitrile / 20% water; gradient length / acquisition time: 100 min or 175 min) an 533 UltiMate 3000 RSLCnano system (Thermo Fisher Scientific GmbH, Dreieich, Germany) was 534 used. Eluting peptides were electrosprayed at 2.3 kV via a Nanospray Flex ion source into a Q 535 Exactive HF-X hybrid quadrupole-orbitrap mass spectrometer (both Thermo Fisher Scientific 536 GmbH, Dreieich, Germany) and analyzed by data-dependent acquisition with HCD (higher 537 energy collisional dissociation) fragmentation of doubly, triply and quadruply charged ions 538 (loop count and dynamic exclusion dependent on the gradient length). Peak lists were 539 generated with ProteoWizard msConvert (http://proteowizard.sourceforge.net/; version 540 3.0.11098), linear shift mass recalibrated (after a preliminary database search) using in-house 541 developed software and searched against a database containing the SARS-CoV-2 UniProtKB reference proteome (proteome ID: UP000464024), all human UniProtKB/Swiss-Prot entries, 542 543 and optionally (to reduce the number of incorrectly assigned matches) selected bacterial 544 proteins (finally the Pseudomonas fluorescens (strain SBW25) reference proteome;

545 proteome ID: UP000002332) with Mascot 2.6.2 (Matrix Science Ltd, London, UK; peptide 546 mass tolerance:  $\pm$  5 ppm; fragment mass tolerance:  $\pm$  20 mmu; one missed trypsin cleavage 547 and common variable modifications allowed).

548

#### 549 Neutralization assay

550 Serum neutralization capacity was analyzed as previously described<sup>56</sup>. Briefly, VeroE6 cells were seeded in 12-well plates at a density of 2.8x10<sup>5</sup> cells/well 24 h prior to infection. Serum 551 552 samples were diluted at ratios of 1:16, 1:32 and 1:64 in 50 µL PBS total volume. Negative 553 controls (PBS without serum) were included for each serum. Diluted sera and negative 554 controls were subsequently mixed with 90 plaque forming units (PFU) of authentic SARS-555 CoV-2 (B.1) in 50 µl PBS (1600 PFU/mL) resulting in final sera dilution ratios of 1:32, 1:64, 556 and 1:128. Following incubation at RT for 1 h, 400 µL PBS was added to each sample and the 557 mixture was subsequently used to infect VeroE6 cells. After 1.5 h of incubation at RT, 558 inoculum was removed and the cells were overlaid with 0.6% Oxoid-agar in DMEM, 20 mM 559 HEPES (pH 7.4), 0.1% NaHCO<sub>3</sub>, 1% BSA and 0.01% DEAE-Dextran. Cells were fixed 48h 560 post-infection (4% formaldehyde for 30 minutes). Upon removal of the agar overlay, plaque 561 neutralization was visualized using 1% crystal violet. PFU were counted manually. Plaques 562 counted for serum-treated wells were compared to the average number of plaques in the 563 untreated negative controls, which were set to 100%.

564

#### 565 Statistical analyses

Statistical analyses were performed using linear statistical models. i.e. the two-group 566 567 comparisons were made based on the t-statistic of the estimated effects. Differences over 568 more than two groups were tested by Analysis of Variance (ANOVA) and multiple testing for 569 subsequent two-group comparisons was then considered by performing Games-Howell post-570 hoc tests. For the time course data, patient differences were treated as random effects in a 571 linear mixed effects model with time and clinical course (severe vs. critical) as fixed main and 572 interaction effects. All analyses were performed at the log<sub>2</sub> scale. Assumptions about variance 573 heterogeneity and normal distribution were checked by visual inspection of diagnostic plots.

574

### 575 Ethics

576 The protocol of this study conforms to the ethical guidelines of the 1975 Declaration of

577 Helsinki and was approved by the institutional ethical committee of the University of Freiburg
578 (EK 153/20). Written informed consent was obtained from participants and the study was

578 (EK 153/20). Written informed consent was obtained from participants and the study was 579 conducted according to federal guidelines, local ethics committee regulations (Albert-

579 conducted according to federal guidelines, local ethics committee regulations (Albert-

580 Ludwigs-Universität, Freiburg, Germany: No. F-2020-09-03-160428 and no. 322/20)

#### 582 Figure Legends

- 583
- 584 Figure 1

## IgG responses against different SARS-CoV-2 proteins across severe and critical clinical course of disease.

587 IgG antibody levels were analyzed in longitudinal serum samples from hospitalized SARS-588 CoV-2 infected individuals. 27 patients were categorized as critically diseased when in need 589 of invasive mechanical ventilation (red symbols) compared to 14 severely diseased patients 590 who did not require invasive ventilation (blue symbols). (A) IgG response against SARS-591 CoV-2 S1 -protein and (B) SARS-CoV-2 N-protein as determined by commercial ELISA 592 assays. Dotted lines represent cut-off values for commercial S1- and N- specific ELISA 593 assays. Each dot represents the mean value obtained by the analysis of all samples which were 594 available at the indicated time points following symptom onset. Solid black lines indicate the 595 median. (C) Serum neutralization capacity against SARS-CoV-2 measured by a plaque 596 reduction assay. Sera were considered neutralizing upon 50% plaque reduction (dotted line) at 597 a 1:64 dilution. Solid black lines indicate the median. Significant differences were tested 598 using a linear mixed effects model (\*\*\*, p<0.001; \*, p<0.05).

599

#### 600 Figure 1-figure supplement 1

## 601 SARS-CoV-2 specific IgG levels in seronegative patients and according to disease 602 outcome.

A) S1- and B) N-specific IgG levels in 30 healthy donors. Solid black lines indicate the
median. C) Cumulative S1-, D) N- and E) RBD-specific IgG levels measured 13-25 days after
symptom onset in deceased (black symbols) and not deceased COVID-19 patients (blue
symbols). Solid black lines indicate the median.

607

## 608 Figure 1-figure supplement 2

# 609 Longitudinal changes in anti- SARS-CoV-2 IgG titers in severely and critically diseased 610 patients.

- 611 Serial serum samples were collected from hospitalized COVID-19 patients and used for
- 612 SARS-CoV-2-specific IgG measurement. IgG responses against SARS-CoV-2 S1- and N-
- 613 protein in (A, C) critically (red symbols) and (B, D) severely (blue symbols) diseased patients.
- 614 Dotted lines represent cut-off values for commercial S1- and N- specific ELISA assays. Each
- 615 symbol represents the mean value of all samples which were available for each patient at the

616 indicated time range after symptom onset. There are no significant t-tests (i.e. p>0.05 for all

617 comparisons).

- 618
- 619 **Figure 2**

## 620 CD16 activation by SARS-CoV-2 - specific IgG is enhanced in critically diseased 621 patients.

622 FcyRIII activation by SARS-CoV-2-specific IgG on BW5147 reporter cells in serum samples 623 obtained 13-25 days following symptom onset from 23 critically (red symbols) and 14 624 severely (blue symbols) diseased patients. Between 2 to 8 samples/patient were analyzed 625 depending on the availability of sample material. Sera from 29 non-hospitalized patients with mild SARS-CoV-2 infection (grey symbols) and 30 healthy donors (open circles) served as 626 627 reference. Each symbol represents the mean value of all available samples per patient. (A, B, 628 C) ELISA levels for S1- N- and RBD-specific IgG. Dotted lines represent cut-off values for 629 commercial S1-, N- and RBD - specific ELISA assays. Solid black lines indicate the mean. 630 (D, E, F) FcyRIII activation by S-, N- and RBD-specific IgG expressed as log<sub>2</sub> fold change 631 relative to negative control. Solid black lines indicate the mean. (G, H, I) FcyRIII activation, 632 expressed as log<sub>2</sub> values relative to SARS-CoV-2-spcific IgG titers. Solid black lines indicate 633 the mean. Significant differences over all three groups were tested by ANOVA and pairwise 634 group comparison was made by Games-Howell post-hoc tests (\*\*\*, p<0.001; \*\*, p<0.01; \*, 635 p<0.05).

636

### 637 Figure 2-figure supplement 1

## 638 Cell-based reporter assay measuring CD16 activation in response to immobilized IgG

639 **and sICs**. BW5147 reporter cells expressing chimeric human Fc $\gamma$ RIII secrete IL-2 in response 640 to Fc $\gamma$ R activation by A) clustered viral specific IgG binding solid-phase antigen or B) soluble 641 ICs. Solubility of sICs is achieved by pre-blocking an ELISA plate with PBS supplemented 642 with 10% FCS as previously described<sup>17</sup>.

643

#### 644 Figure 2-figure supplement 2

#### 645 Dose dependent CD16 activation by SARS-CoV-2 specific IgG.

646 CD16 activation by A) S- , B) N- and C) RBD-specific IgG in 9 representatively selected 647 serum samples and one SARS-CoV-2 negative serum (dark blue bars). Sera were serially 648 diluted at 1:20, 1:100, 1:500 and 1:2500. FcγRIII activation initiates IL-2 secretion by 649 reporter cells, which is subsequently measured via ELISA (OD 450 nm). Based on this empirical pretesting all sera were thereafter tested at 1:100 and 1:500 dilutions to reach an
optimal dynamic range of response. The OD values obtained by the 1:500 dilutions were used
for subsequent data analysis.

653

#### 654 Figure 2-figure supplement 3

Reproducibility of CD16 activation measurements by SARS-CoV-2 specific IgG. Selected sera which were available in sufficient amount from patients with critical (red symbols) or severe (blue symbols) SARS-CoV-2 infection were tested in two independent experiments to show reproducibility and consistency of results. CD16 activation by S-, N- and RBD specific IgG is shown. Statistical tests using a Kolmogorov-Smirnov test indicate no significant differences.

661

### 662 Figure 2-figure supplement 4

## 663 Correlation of CD16 activation by virus specific IgG and ELISA levels.

Pearson's correlation coefficient was used to assess the relationship between virus–specific IgG levels and their capability to trigger CD16 activation on BW5147 reporter cells in 22 paired samples from patients with critical disease (red symbols), 14 paired samples from patients with severe disease (blue symbols) and 28 samples from patients with mild disease (grey symbols). Each dot represents the mean value obtained by the analysis of all samples available at the indicated time points. (A-C) anti-S IgG, (D-F) anti-N IgG and anti-RBD-IgG (E-I).

671

#### 672 **Figure 3**

### 673 Anti SARS-CoV-2 IgG Fc core fucosylation in critical and severe COVID-19 cases.

674 IgG-Fc core fucosylation levels of SARS-CoV-2 -specific IgG in critically (red bars) and severely (blue bars) diseased COVID-19 patients. Analysis was carried out on a pool of 5 675 676 different sera. Measured OD values for fucosylation of the generated eluates were normalized 677 to their respective IgG titers determined by antigen-specific S1 and N ELISA. A) S-IgG-Fc-678 fucosylation and B) N-IgG-Fc-fucosylation in critically and severely diseased patients 679 characterized by either high (red) or low (patterned) CD16-activation levels in the FcyR 680 activation reporter assay. The mean and standard deviation (SD) of at least three independent 681 experiments is depicted. Statistical tests using a two-factorial linear model indicate three 682 significant differences between the low and high categories (\*\*\*, p<0.001; \*\*, p<0.01; \*, 683 p < 0.05; ns = not significant).

#### 684 Figure 4

### 685 Severe COVID-19 disease coincides with high CD16 activation by sICs.

686 Serial serum samples obtained 13-25 days after onset of symptoms were analyzed in a cell-687 based reporter assay which is sensitive to sIC amount and size<sup>16</sup>. Fc $\gamma$ R activation is shown as log<sub>2</sub> fold change relative to negative control. Each symbol represents the mean value obtained 688 689 by the analysis of all samples available in the indicated time range for each individual patient. 690 A) Analysis of CD16 activation by sICs in SARS-CoV-2-infected patients compared to healthy blood donors B) Levels of IC-mediated CD16 activation across severe, critical and 691 692 mild clinical courses of COVID-19 disease, in healthy donors (HD) and in non-COVID-19patients who developed acute respiratory distress syndrome (ARDS). Solid black lines 693 694 indicate the mean. Two-group comparisons with the linear model indicate significant 695 differences between critical cases and all other groups, as well as between severe cases and all other groups (\*\*\*, p<0.001; \*\*, p<0.01). No significant differences (p>0.05) have been found 696 697 for the comparisons mild vs. healthy and for HD vs. ARDS. C) Kinetics of IC-mediated CD16 698 activation in critically and severely diseased patients. Solid black lines indicate the median. 699 The mixed effects model indicates two time points with significant differences (\*\*, p<0.01; \*, 700 p<0.05).

701

#### 702 Figure 4-figure supplement 1

#### 703 CD16 activation by sICs in non-COVID-19 patients with ARDS.

Serum samples from 47 patients with ARDS in response to infections of different etiology
were analyzed in a cell-based reporter assay which is sensitive to sIC amount and size<sup>16</sup>. FcγR
activation is shown as log<sub>2</sub> fold change relative to negative control. Each symbol represents
one sample from one patient. CMV: Cytomegalovirus reactivation under immunosuppression;
HIV: HIV infection; TBC: Mycobacterium tuberculosis infection; Influenza: influenza virus
infection; TX: solid organ transplantation. Solid black lines indicate the median.

710

#### 711 Figure 4-figure supplement 2

#### 712 PEG precipitation eliminates sIC-mediated CD16 activation.

Pools of 8 sera were incubated with equal volumes of PEG8000 to reach the indicated final PEG concentrations. A) CD16 activation after PEG-precipitation in the pool supernatant, showing either high (sICs+) or no (sICs-) CD16 activation. Sera from healthy donors (HD) were included as a negative control. Activation levels are expressed as IL-2 levels (OD 450 nm) released by reporter cells. The mean and SD of two independent experiments is depicted. 718 B) Anti SARS-CoV-2 IgG levels against S1 (left panel) or N (right panel) IgG following PEG

- 719 precipitation. The mean and SD of two independent experiments (sIC+/sIC-) is depicted.
- 720

### 721 Figure 4-figure supplement 3

## Individual CD16 activation by sICs and anti-S1 ELISA IgG kinetics post symptoms onset.

724 Individual sera for either critically or severely diseased patients were analyzed in order to 725 detect anti S1-IgG antibodies (top panel) via Euroimmune ELISA [AU] and CD16 activation 726 by soluble immune complexes (lower panel, relative CD16 activation depicted as fold 727 increase to the negative control) over time (1-40 days post symptom onset). White panel: not 728 tested.

729

### 730 Figure 4-figure supplement 4

## 731 Benzonase treatment of sIC-reactive sera does not abolish CD16 activation.

Left panel: sIC-mediated CD16 reactivity expressed as log<sub>2</sub> fold increase to the negative control, in serum of six individual patients before and after treatment with 250 Units of Benzonase Nuclease. Right panel: As positive control, 3 µg plasmid DNA was digested. M: 1kb DNA ladder, Lane 1: benzonase digestion in the presence of human serum, lane 2: plasmid DNA w/o benzonase in the presence of human serum, lane 3: benzonase digestion in medium only and lane 4: plasmid DNA w/o benzonase in medium only.

- 738
- 739

## 740 **Figure 5**

## Summary of antibody features from SARS-CoV-2-infected patients with critical and severe disease.

Relative multivariate antibody features illustrated as radar chart in critically (red) or severely (blue) diseased COVID-19 patients normalized to the corresponding features of patients with mild infection (grey). Each spoke represents one of the following variables: ELISA (S1-IgG, N-IgG,) and CD16 activation (S-IgG, N-IgG, sICs). Arithmetic mean values of log<sub>2</sub> values were calculated for each group (days 13-25 post symptom onset) respectively. The fold change compared to mildly diseased patients is shown.

- 749
- 750
- 751

## 752 **Table 1**

## 753 Clinical characteristics of the hospitalized SARS-CoV-2 patients.

- 754 Patients were categorized as either severely (hospitalized, requiring O<sub>2</sub> supplementation,
- 755 n=14) or critically diseased (hospitalized and in need of invasive mechanical ventilation,
- 756 n=27). Diagnostic markers are depicted as mean and SD (in brackets) of all analyzed
- 13-25 days post symptom onset. Percentage [%] is indicated.

#### 758 **References**

- 760
   1
   Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J

   761
   Med **382**, 727-733, doi:10.1056/NEJMoa2001017 (2020).
- 762
   2
   Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real

   763
   time. Lancet Infect Dis 20, 533-534, doi:10.1016/S1473-3099(20)30120-1 (2020).
- 7643Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus765disease 2019. J Clin Invest 130, 2620-2629, doi:10.1172/JCl137244 (2020).
- 7664Felsenstein, S., Herbert, J. A., McNamara, P. S. & Hedrich, C. M. COVID-19: Immunology and767treatment options. *Clin Immunol* **215**, 108448, doi:10.1016/j.clim.2020.108448 (2020).
- 7685Magleby, R. et al. Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality769Among Hospitalized Patients with Coronavirus Disease 2019. Clin Infect Dis,770doi:10.1093/cid/ciaa851 (2020).
- Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Correction to: Clinical predictors of mortality
  due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 46, 1294-1297, doi:10.1007/s00134-020-06028-z (2020).
- 774 7 Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19
  775 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062, doi:10.1016/S0140776 6736(20)30566-3 (2020).
- Yang, X. *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2
  pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 8, 475-481, doi:10.1016/S2213-2600(20)30079-5 (2020).
- 780 9 Zhou, Y. *et al.* Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in
  781 severe COVID-19 patients. *National Science Review* 7, 998-1002, doi:10.1093/nsr/nwaa041
  782 (2020).
- 78310Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* 26,784845-848, doi:10.1038/s41591-020-0897-1 (2020).
- 785
   11
   Zhang, J. M. & An, J. Cytokines, inflammation, and pain. Int Anesthesiol Clin 45, 27-37,
   786
   doi:10.1097/AIA.0b013e318034194e (2007).
- Vogelpoel, L. T., Baeten, D. L., de Jong, E. C. & den Dunnen, J. Control of cytokine production
  by human fc gamma receptors: implications for pathogen defense and autoimmunity. *Front Immunol* 6, 79, doi:10.3389/fimmu.2015.00079 (2015).
- 790
   13
   Bruhns, P. & Jonsson, F. Mouse and human FcR effector functions. *Immunol Rev* 268, 25-51,

   791
   doi:10.1111/imr.12350 (2015).
- 79214Zubler, R. H. *et al.* Circulating and intra-articular immune complexes in patients with793rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological794features of the disease. J Clin Invest 57, 1308-1319, doi:10.1172/JCl108399 (1976).
- 79515Levinsky, R. J. Role of circulating soluble immune complexes in disease. Arch Dis Child 53, 96-79699, doi:10.1136/adc.53.2.96 (1978).
- 79716Levinsky, R. J., Cameron, J. S. & Soothill, J. F. Serum immune complexes and disease activity798in lupus nephritis. Lancet 1, 564-567, doi:10.1016/s0140-6736(77)91998-5 (1977).
- 79917Chen, H. et al. FcγR responses to soluble immune complexes are governed by solubility and<br/>size. bioRxiv, 2020.2011.2011.378232, doi:10.1101/2020.11.11.378232 (2021).
- 80118Wang, T. T. & Ravetch, J. V. Immune complexes: not just an innocent bystander in chronic802viral infection. Immunity 42, 213-215, doi:10.1016/j.immuni.2015.01.022 (2015).
- Carreno, L. J., Pacheco, R., Gutierrez, M. A., Jacobelli, S. & Kalergis, A. M. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells. *Immunology* 128, 334-341, doi:10.1111/j.1365-2567.2009.03138.x (2009).
- 80720Faik, I. *et al.* Pyruvate Kinase and Fcgamma Receptor Gene Copy Numbers Associated With808Malaria Phenotypes. J Infect Dis **216**, 276-282, doi:10.1093/infdis/jix284 (2017).

- 80921Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress810syndrome. Lancet Respir Med 8, 420-422, doi:10.1016/S2213-2600(20)30076-X (2020).
- 811 22 Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections: causes and
  812 consequences of cytokine storm and immunopathology. *Seminars in Immunopathology* 39,
  813 529-539, doi:10.1007/s00281-017-0629-x (2017).
- 81423Smits, S. L. *et al.* Exacerbated innate host response to SARS-CoV in aged non-human815primates. *PLoS Pathog* 6, e1000756, doi:10.1371/journal.ppat.1000756 (2010).
- 81624Rockx, B. et al. Early upregulation of acute respiratory distress syndrome-associated817cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory818syndrome coronavirus infection. J Virol 83, 7062-7074, doi:10.1128/JVI.00127-09 (2009).
- 81925Hoepel, W. et al. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG820promote inflammation by alveolar macrophages. Sci Transl Med 13,821doi:10.1126/scitranslmed.abf8654 (2021).
- 82226Zohar, T. & Alter, G. Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev823Immunol 20, 392-394, doi:10.1038/s41577-020-0359-5 (2020).
- 82427Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector825functions in infectious diseases. Nat Rev Immunol 18, 46-61, doi:10.1038/nri.2017.106826(2018).
- 827 28 Corrales-Aguilar, E. et al. A novel assay for detecting virus-specific antibodies triggering 828 activation of Fe gamma receptors. J Immunol Methods 387, 21-35, 829 doi:10.1016/j.jim.2012.09.006 (2013).
- 83029Chakraborty, S. *et al.* Proinflammatory IgG Fc structures in patients with severe COVID-19.831Nat Immunol 22, 67-73, doi:10.1038/s41590-020-00828-7 (2021).
- 83230High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation833by alveolar macrophages. Sci Transl Med, doi:10.1126/scitranslmed.abf8654 (2021).
- 83431Larsen, M. D. *et al.* Afucosylated IgG characterizes enveloped viral responses and correlates835with COVID-19 severity. *Science* **371**, doi:10.1126/science.abc8378 (2021).
- Li, T. *et al.* Modulating IgG effector function by Fc glycan engineering. *Proceedings of the National Academy of Sciences of the United States of America* **114**, 3485-3490,
  doi:10.1073/pnas.1702173114 (2017).
- 839 33 Roncati, L. *et al.* Type 3 hypersensitivity in COVID-19 vasculitis. *Clinical Immunology* 217, doi:ARTN 108487
- 841 10.1016/j.clim.2020.108487 (2020).
- Roe, K. High COVID-19 virus replication rates, the creation of antigen-antibody immune
  complexes and indirect haemagglutination resulting in thrombosis. *Transbound Emerg Dis*67, 1418-1421, doi:10.1111/tbed.13634 (2020).
- 84535Zhang, Y. et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N846Engl J Med **382**, e38, doi:10.1056/NEJMc2007575 (2020).
- 84736Creighton, W. D., Lambert, P. H. & Miescher, P. A. Detection of antibodies and soluble848antigen-antibody complexes by precipitation with polyethylene glycol. J Immunol 111, 1219-8491227 (1973).
- 85037Veras, F. P. et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19851pathology. J Exp Med 217, doi:10.1084/jem.20201129 (2020).
- 85238Horwitz, J. A. *et al.* Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.853*Cell* **170**, 637-648 e610, doi:10.1016/j.cell.2017.06.048 (2017).
- 85439Forthal, D. N. & Moog, C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 4,855388-393, doi:10.1097/COH.0b013e32832f0a89 (2009).
- 85640DiLillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-857specific antibodies require FcgammaR interactions for protection against influenza virus in858vivo. Nat Med 20, 143-151, doi:10.1038/nm.3443 (2014).
- 85941Hessell, A. J. *et al.* Fc receptor but not complement binding is important in antibody860protection against HIV. *Nature* **449**, 101-104, doi:10.1038/nature06106 (2007).

- Li, K. *et al.* Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. *Nature communications* **11**, 6044, doi:10.1038/s41467-020-19943-y 863
  (2020).
- 86443Ogata, A. F. *et al.* Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-8651273 Vaccine Recipients. *Clin Infect Dis*, doi:10.1093/cid/ciab465 (2021).
- 86644Zhang, L. *et al.* SARS-CoV-2 spike-protein D614G mutation increases virion spike density and867infectivity. *Nature communications* **11**, 6013, doi:10.1038/s41467-020-19808-4 (2020).
- Letarov, A. V., Babenko, V. V. & Kulikov, E. E. Free SARS-CoV-2 Spike Protein S1 Particles May
  Play a Role in the Pathogenesis of COVID-19 Infection. *Biochemistry (Mosc)* 86, 257-261,
  doi:10.1134/S0006297921030032 (2021).
- 87146Woodruff, M. C. *et al.* Extrafollicular B cell responses correlate with neutralizing antibodies872and morbidity in COVID-19. Nat Immunol 21, 1506-1516, doi:10.1038/s41590-020-00814-z873(2020).
- 87447Wang, E. Y. *et al.* Diverse functional autoantibodies in patients with COVID-19. Nature,875doi:10.1038/s41586-021-03631-y (2021).
- 48 Zuo, Y. *et al.* Prothrombotic autoantibodies in serum from patients hospitalized with COVID877 19. *Sci Transl Med* 12, doi:10.1126/scitranslmed.abd3876 (2020).
- 87849Chang, S. E. *et al.* New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19.879*medRxiv*, doi:10.1101/2021.01.27.21250559 (2021).
- 88050Bastard, P. *et al.* Autoantibodies against type I IFNs in patients with life-threatening COVID-88119. Science **370**, doi:10.1126/science.abd4585 (2020).
- Heidelberger, M. & Kendall, F. E. A Quantitative Study of the Precipitin Reaction between
  Type Iii Pneumococcus Polysaccharide and Purified Homologous Antibody. *J Exp Med* 50,
  884 809-823, doi:10.1084/jem.50.6.809 (1929).
- Gharebaghi, N., Nejadrahim, R., Mousavi, S. J., Sadat-Ebrahimi, S. R. & Hajizadeh, R. The use
  of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease
  2019: a randomized placebo-controlled double-blind clinical trial. *BMC Infect Dis* 20, 786,
  doi:10.1186/s12879-020-05507-4 (2020).
- 88953Kolb, P. *et al.* Identification and Functional Characterization of a Novel Fc Gamma-Binding890Glycoprotein in Rhesus Cytomegalovirus. J Virol **93**, doi:10.1128/JVI.02077-18 (2019).
- 891
   54
   Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat* 

   892
   *Med* 26, 1033-1036, doi:10.1038/s41591-020-0913-5 (2020).
- 89355Pandey, A., Andersen, J. S. & Mann, M. Use of mass spectrometry to study signaling<br/>pathways. *Sci STKE* 2000, pl1, doi:10.1126/stke.2000.37.pl1 (2000).
- 89556Tönshoff, B. *et al.* Prevalence of SARS-CoV-2 Infection in Children and Their Parents in896Southwest Germany. JAMA Pediatrics 175, 586-593, doi:10.1001/jamapediatrics.2021.0001897(2021).
- 898
- 899
- 900

901

#### 902 Acknowledgements

903 We thank Sophia Ruben and Torsten Schulz from InVivo Bio Tech Services for peparing 904 SARS-CoV-2 (S)- and RBD- coated plates and preparing the SARS-CoV-2 IgG ELISA 905 Reagent Set. We thank Hans-Martin Jäck for providing TRES-1-224.2.19 and TRES-II-480 906 monoclonal antibodies and Quinnlan David for critically reading the manuscript. We also 907 thank Andreas Schlosser for validation of our Mass Spectrometry data. This work was 908 supported by the Bundesministerium fuer Bildung und Forschung (BMBF) through the 909 Deutsches Zentrum fuer Luft- und Raumfahrt, Germany, (DLR, grant number 01KI2077) and 910 by the Federal State of Baden-Wuerttemberg, Germany, MWK-Sonderfoerdermaßnahme 911 COVID-19/AZ.:33-7533.-6-21/7/2 to MS. This work was also supported by an intramural 912 junior investigator fund of the Faculty of Medicine to PK (Hans A. Krebs - Funding for 913 Medical Scientists, Faculty of Medicine, University of Freiburg) and "NaFoUniMedCovid19" 914 (FKZ: 01KX2021 - COVIM to H.H., FKZ 100493916 B-FAST to H.H.) and DFG HE2526/9-915 1 to H.H.. A. Lother is a member of SFB1425, funded by the Deutsche 916 Forschungsgemeinschaft (DFG, German Research Foundation #422681845). The funders had 917 no role in the study design, data analysis, data interpretation, and in the writing of this report. 918 All authors had full access to the data in the study and accept responsibility to submit for 919 publication.

920

#### 921 Author contribution:

922 Conceived and designed the experiments: J.A., A.M-P., S.G., P.K., A.L, V.F., M.S., H.H.

- 923 Performed the experiments: J.A., N.G., U.S., S.G., K. C., W.B.
- 924 Analyzed the data: J.A., S.G., P.K., V.F., K.C., A.M-P., W.B., C.K.
- 925 Contributed/reagent/sample material: A.B.G., D.H., T.W., N.G.M.
- 926 Writing and original draft preparation: J.A., S.G., P.K., V.F.

bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

927

- 928 Review and editing: H.H., M.S., K.C.
- 929 Conceptualization: V.F., H.H.

930

- 931 **Competing interests:** The authors declare the following competing financial interest(s):
- 932 InVivo BioTech Services is a biotechnology company producing antibodies and proteins,
- 933 including SARS-CoV-2 antigens.
- 934 Data and materials availability: All data associated with this study are present in the paper
- 935 or Supplementary Materials.

bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

## 937 Figures and Tables


## 

## **Table 1**


	All patients n: 41	%	critical n: 27	%	severe n: 14	%						
Age [years]	Ø 68 (31-90)	-	Ø 63 (39-79)	-	Ø 76 (31-90)	-						
Female	8	19.5	5	18.5	3	21.4						
Male	33	80.5	22	81.5	11	78.6						
Comorbidities												
Hypertension	21	51.2	12	44.4	9	64.3						
Cardiovascular disease	14	34.1	5	18.5	9	64.3						
Pulmonary disease	6	14.6	2	7.4	4	28.6						
Chronic kidney disease	6	14.6	31 (39)7 (37)		5	35.7						
Diabetes	10	24.4 6		22.2	4	28.6						
Malignancy	8	19.5	4	14.8	4	28.6						
none	6	14.6	6	22.2	0	0						
	Diago	ostic	markers									
			1452.1		46.1							
Interleukin-6 [pg/ml] Ø	1012.8	-	(3774.6)	-	(26.8)	-						
Procalcitonin [ng/ml] Ø	7	- 9.9 (21.9)		-	0.17 (0.11)	-						
C- reactive protein [mg/l] Ø	128.1	-	162.2 (75.8)	-	65.3 (47.1)	-						
						·						
De staviel sur avie fa stieve		mplica		40.7	-	05.7						
Bacterial superinfection	16	39	11	40.7	5	35.7						
Treatment												
Hydroxychloroquine, Ritonavir+ Lopinavir (Kaletra®)	24	58.5	18	66.7	6	42.9						
Fatal outcome												
Total	11	26.8	10	37	1	7.1						

bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.






bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.




## 949 Figure 1 – figure supplement 2




bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.


951 Figure 2



## 954 Figure 2 – figure supplement 1


## 





bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.


## 958 Figure 2 – figure supplement 2



959


bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

## 961 Figure 2 – figure supplement 3



962


#### 964 Figure 2 – figure supplement 4




965

bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.


## 967 Figure 3




## 970 Figure 4



## 973 Figure 4 – figure supplement 1



## 976 Figure 4 – figure supplement 2




#### 978 Figure 4 – figure supplement 3

critical	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$				
severe	1				13 10 7 4

days after symptom onset

bioRxiv preprint doi: https://doi.org/10.1101/2021.06.25.449893; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

## 980 Figure 4 – figure supplement 4



## 982 Figure 5

